

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIFE HEALTHCARE GROUP LIMITED

蓮和醫療健康集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 928)

CHANGE OF DIRECTORS CHANGE IN COMPOSITION OF BOARD COMMITTEES AND CHANGE OF AUTHORISED REPRESENTATIVE

The Board hereby announces that with effect from 6 December 2021:

- (1) Mr. Pang Zhen has been appointed as an executive Director and an Authorised Representative;
- (2) Mr. Wang Yang has been appointed as an independent non-executive Director, chairman and a member of the Audit Committee, chairman and a member of the Nomination Committee and a member of the Remuneration Committee; and
- (3) Mr. Xu Xueping has been resigned as chairman of the Board, an executive Director, chairman and a member of the Nomination Committee, a member of the Remuneration Committee and an Authorised Representative.

The board (the “**Board**”) of directors (“**Directors**”) of Life Healthcare Group Limited (the “**Company**”) announces the followings:

APPOINTMENT OF EXECUTIVE DIRECTOR AND AUTHORISED REPRESENTATIVE

The board is pleased to announce that Mr. Pang Zhen (“**Mr. Pang**”) has been appointed as an executive Director and an authorised representative of the Company (“**Authorised Representative**”) for the purposes of Rule 3.05 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (“**Listing Rules**”) with effect from 6 December 2021.

Mr. Pang, aged 45, graduated from the real estate operation and management major of the Department of Civil Engineering of Anshan Iron and Steel College in July 1998. Mr. Pang has over 20 years work experience in the real estate industry in PRC, mainly engaged in the development, sales and leasing activities of properties in PRC since graduation from college in 1998.

Mr. Pang has not held (i) any other position in the Company and other members of the Group; (ii) any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As the date of this announcement, Mr. Pang has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company (having the meaning ascribed to it in the Listings Rules). Mr. Pang is a substantial shareholder of the Company holding approximately 22.18% of the issued share capital of the Company.

Under the letter of appointment entered into between Mr. Pang and the Company, Mr. Pang's term of service is 2 years and automatically renewed for another 2 years upon expiry date unless terminate by either party with prior notice. His directorship in the Company is subject to rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company ("**Articles of Association**"). The remuneration of Mr. Pang is HK\$10,000 per month which is determined by the Board and the Remuneration Committee with reference to his experience, duties and responsibilities within the Company.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Pang that need to be brought to the attention of the shareholders of the Company ("**Shareholders**") and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, CHAIRMAN AND MEMBER OF EACH OF AUDIT COMMITTEE AND NOMINATION COMMITTEE AND MEMBER OF REMUNERATION COMMITTEE

The board is pleased to announce that Mr. Wang Yang ("**Mr. Wang**") has been appointed as an independent non-executive Director, chairman and a member of the audit committee of the Company ("**Audit Committee**"), chairman and a member of the nomination committee of the Company ("**Nomination Committee**") and a member of the remuneration committee of the Company ("**Remuneration Committee**") with effect from 6 December 2021.

Mr. Wang, aged 36, graduated from Miyun Campus of Capital University of Economics and Business major in Business Management in 2006. Mr. Wang has approximately 14 years work experience in the film industry in PRC mainly engaged in finance and production of films. At present, Mr. Wang is working as a self-employed marketing executive in a securities firm in Beijing.

Mr. Wang has not held (i) any other position in the Company and other members of the Group; (ii) any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As the date of this announcement, Mr. Wang has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company (having the meaning ascribed to it in the Listing Rules) and does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Under the letter of appointment entered into between Mr. Wang and the Company, Mr. Wang's term of service is 2 years. His directorship in the Company is subject to rotation and re-election at annual general meetings of the Company in accordance with the Articles of Association of the Company. The remuneration of Mr. Wang is HK\$10,000 per month which is determined by the Board and the Remuneration Committee with reference to his experience, duties and responsibilities within the Company.

Mr. Wang confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Wang that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express a warm welcome to Mr. Pang and Mr. Wang for joining the Board.

RESIGNATION OF CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR, CHAIRMAN AND MEMBER OF NOMINATION COMMITTEE, MEMBER OF REMUNERATION COMMITTEE AND AUTHORISED REPRESENTATIVE

Mr. Xu Xueping (“**Mr. Xu**”) has been resigned as chairman of the Board, an executive Director, chairman and a member of the Nomination Committee, a member of the Remuneration Committee and an Authorised Representative with effect from 6 December 2021 in order to focus his time and effect on other business commitments. Mr. Xu has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation which need to be brought to the attention of the Shareholders or The Stock Exchange of Hong Kong Limited.

The Board would like to express its gratitude and appreciation to Mr. Xu for his contribution to the Company during his term of office.

COMPLIANCE WITH RULES 3.10(1) AND 3.21 OF THE LISTING RULES

Following the appointment of Mr. Wang as an independent non-executive Director, chairman and member of the Audit Committee, the Company has complied with the requirements of (i) having at least three independent non-executive Directors on the Board under rule 3.10(1) of the Listing Rules; and (ii) having a minimum of three non-executive directors in the audit committee under rule 3.21 of the Listing Rules.

By order of the Board
Life Healthcare Group Limited
Pang Zhen
Executive Director

Hong Kong, 6 December 2021

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Man Wai Lun

Mr. Pang Zhen

Independent non-executive Directors:

Mr. Liu Xinghua

Mr. Li Li

Mr. Wang Yang

Non-executive Director:

Ms. Fu Xiaoji